Skip to main content
SpringerLink
Log in

Screening for immunocompromise essential before Zostavax use

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Therapeutic Goods Administration. Safety advisory - careful assessment and screening for immunocompromise essential before administration of Zostavax Internet Document : 17 Feb 2022. Available from: URL: https://www.tga.gov.au/alert/zostavax

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Screening for immunocompromise essential before Zostavax use. Reactions Weekly 1896, 4 (2022). https://doi.org/10.1007/s40278-022-10795-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-10795-3

Search

Navigation